Navigation Links
Two-Drug Combo Fights Brain Tumors

Avastin, irinotecan may hit the cancer at different points, researchers say

FRIDAY, Oct. 19 (HealthDay News) -- A combination of the drug bevacizumab (brand name Avastin) and the standard chemotherapy agent irinotecan may benefit patients with a type of deadly brain tumor called glioblastoma multiforme (GBM), says a Duke University pilot study.

This treatment approach may extend the length of time GBM patients can survive without tumor growth and may improve overall survival, according to researchers at Duke's Preston Robert Tisch Brain Tumor Center.

The study included 35 patients whose GBMs returned after they'd had standard therapy, possibly including surgery, radiation and chemotherapy. After the patients received the combination bevacizumab/irinotecan therapy, almost half had no tumor progression after six months, and 80 percent were still alive six months after diagnosis.

The findings are published in the Oct. 20 issue of the Journal of Clinical Oncology.

"These results represent tremendous hope for these patient and their families," lead investigator Dr. James J. Vredenburgh, a neuro-oncologist, said in a prepared statement.

He noted that 75 percent of patients with recurrent GBM treated with standard therapy, such as chemotherapy alone, have tumor progression at six months, and fewer than 50 percent are alive after six months.

"We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently, or they work together, with bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy," Vredenburgh said.

"Further studies will tease out the exact mechanism of the therapy's success, and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM," he added.

More information

The U.S. National Cancer Institute has more about brain tumors.

-- Robert Preidt

SOURCE: Duke University, news release, Oct. 18, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Two-Drug Regime To Tackle Malaria
2. Drug Combo Works Better for children with ADHD, Tics
3. Scanning Combo Helps Detect Lung Cancer
4. Relief From Asthma With New Combo Therapy
5. Calcium-Vitamin D Combo For Reduced Fracture Risk
6. Drug Combo Improves Performance Of Multiple Sclerosis Drug
7. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
8. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
9. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
10. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
11. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... workers from extreme heat at their worksites. Employers with workers exposed to ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: